Bipolar Disorder

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

There was a decrease in relapse observed for low-risk participants, but not high-risk individuals.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control.

The treatment is approved as either a monotherapy or an adjunctive therapy with either lithium or valproate.

Circadian disruption presented across a variety of high-risk, prodromal, and syndromic psychiatric disorders.

Higher depressive and manic (symptoms were associated with lower GAF, most strongly among the older participants.

Severe mental disorders had the highest odds ratios for the risk of mortality.

Lamotrigine is currently being used as a maintenance therapy for bipolar disorder.

New data show significant therapeutic effects of dextraomethadone treatment in MDD patients below the median percentage of life-years from diagnosis.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

A higher percentage of patients suffering from a severe mental disorder such as schizophrenia or bipolar disorder, died from a COVID-19 infection than the control group.

Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.

Both monotherapy and combination of the unique regimen was shown to improve manic and depressive status at 12 weeks.

Repeated Transcranial Magnetic Stimulation shows more efficacy treating bipolar disorder than schizophrenia.

The agency did not find any efficacy or safety issues regarding the potential treatment for adults with schizophrenia or bipolar I disorder.

Patients with bipolar depression have struggled during the COVID-19 pandemic.

Association with familial history found in hospitalizations, suicide attempts, and an earlier onset of symptoms.

There were no significant differences observed in mood episodes for bipolar patients in either AISR therapy or standard treatment.

An analysis of 20-year outpatient prescribing trends show the drug class is being favored over mood stabilizers.

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

How have natural-cause mortality rates changed over time in an international population?

How psychiatry can catch up to other specialties in accurate, timely diagnostics based on molecular breakthrough.

A public health expert shares insight on the positives and pitfalls learned from stigma-reduction campaigns.

Investigators find link between childhood psychopathology and polygenetic scores in a number of disorders, but not bipolar disorder.

PDUFA target action date set for November 15, 2020 for the new combination olanzapine/samidorphan treatment.

Investigators found that family involvement in treatment can prolong the time between recovery and the next mood episode.